bpc 157 half life pharmacokinetics BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 Micro-Dosing: Is Less More
Description
Removing the middleman: From vapor to solid and back again
LeRoith D, Gavrilova O
The vial goes cloudy, the peptide aggregates, and the dose is non-functional
How many doses are in an R-30 vial
, Gu, J
In those cases the unit math changes a 0.25 mg dose at 3 mg/ml is about 8 units, not 25
